Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombolytic Therapy | 6 | 2025 | 261 | 1.570 |
Why?
|
| Pulmonary Embolism | 4 | 2022 | 235 | 1.220 |
Why?
|
| Cardiac Tamponade | 2 | 2018 | 23 | 1.130 |
Why?
|
| Thrombosis | 6 | 2021 | 326 | 0.780 |
Why?
|
| Haemophilus influenzae | 2 | 2018 | 17 | 0.730 |
Why?
|
| Haemophilus Infections | 1 | 2018 | 9 | 0.560 |
Why?
|
| Vascular Neoplasms | 1 | 2018 | 21 | 0.550 |
Why?
|
| Leiomyosarcoma | 1 | 2018 | 49 | 0.530 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 232 | 0.530 |
Why?
|
| Renal Veins | 1 | 2017 | 29 | 0.510 |
Why?
|
| Catheterization, Central Venous | 1 | 2018 | 120 | 0.510 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 34 | 0.510 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 143 | 0.510 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 90 | 0.480 |
Why?
|
| Catheterization | 1 | 2017 | 238 | 0.470 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2022 | 181 | 0.460 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 394 | 0.420 |
Why?
|
| Anticoagulants | 3 | 2021 | 463 | 0.400 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 145 | 0.390 |
Why?
|
| Recycling | 1 | 2012 | 3 | 0.390 |
Why?
|
| Water Purification | 1 | 2012 | 4 | 0.390 |
Why?
|
| Waste Disposal, Fluid | 1 | 2012 | 3 | 0.390 |
Why?
|
| Filtration | 1 | 2012 | 27 | 0.380 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 303 | 0.380 |
Why?
|
| Venous Thrombosis | 3 | 2025 | 257 | 0.370 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 298 | 0.370 |
Why?
|
| Ultrasonic Therapy | 2 | 2025 | 44 | 0.370 |
Why?
|
| Fibrinolytic Agents | 4 | 2022 | 240 | 0.370 |
Why?
|
| Tissue Engineering | 1 | 2013 | 202 | 0.360 |
Why?
|
| Water Pollutants, Chemical | 1 | 2012 | 140 | 0.340 |
Why?
|
| Heparin | 2 | 2021 | 187 | 0.330 |
Why?
|
| Cardiac Catheterization | 5 | 2016 | 330 | 0.310 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 2 | 2021 | 48 | 0.310 |
Why?
|
| Shock, Cardiogenic | 4 | 2016 | 172 | 0.300 |
Why?
|
| Heart-Assist Devices | 5 | 2016 | 898 | 0.290 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2013 | 143 | 0.260 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1276 | 0.260 |
Why?
|
| Biomarkers | 4 | 2021 | 1933 | 0.250 |
Why?
|
| Exercise Therapy | 1 | 2007 | 94 | 0.250 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 437 | 0.230 |
Why?
|
| Nitric Oxide | 1 | 2007 | 281 | 0.230 |
Why?
|
| Femoral Vein | 1 | 2025 | 42 | 0.220 |
Why?
|
| Stem Cells | 1 | 2007 | 394 | 0.210 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2019 | 217 | 0.210 |
Why?
|
| Humans | 28 | 2022 | 96127 | 0.210 |
Why?
|
| Aortic Valve | 2 | 2017 | 273 | 0.190 |
Why?
|
| Phantoms, Imaging | 3 | 2021 | 491 | 0.190 |
Why?
|
| Fibrinolysis | 1 | 2022 | 37 | 0.180 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2021 | 61 | 0.170 |
Why?
|
| Echocardiography, Transesophageal | 5 | 2016 | 362 | 0.170 |
Why?
|
| Embolectomy | 1 | 2020 | 7 | 0.170 |
Why?
|
| Antithrombins | 1 | 2020 | 18 | 0.170 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2017 | 528 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 97 | 0.160 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 51 | 0.160 |
Why?
|
| Middle Aged | 16 | 2021 | 28363 | 0.160 |
Why?
|
| Europe | 1 | 2020 | 349 | 0.150 |
Why?
|
| Female | 16 | 2021 | 50063 | 0.150 |
Why?
|
| Elastic Modulus | 1 | 2019 | 39 | 0.150 |
Why?
|
| Gels | 1 | 2019 | 53 | 0.150 |
Why?
|
| Lithotripsy | 1 | 2019 | 45 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2020 | 238 | 0.150 |
Why?
|
| Microbubbles | 1 | 2019 | 41 | 0.150 |
Why?
|
| Recurrence | 2 | 2020 | 1218 | 0.150 |
Why?
|
| Cardiology | 1 | 2020 | 130 | 0.150 |
Why?
|
| Aged | 12 | 2021 | 20964 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2021 | 744 | 0.150 |
Why?
|
| Administration, Oral | 1 | 2020 | 688 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2022 | 9173 | 0.150 |
Why?
|
| Acute Disease | 1 | 2020 | 872 | 0.140 |
Why?
|
| Pericardiocentesis | 1 | 2018 | 7 | 0.140 |
Why?
|
| Pericarditis | 1 | 2018 | 16 | 0.140 |
Why?
|
| Hospital Costs | 1 | 2019 | 117 | 0.140 |
Why?
|
| Binge Drinking | 1 | 2018 | 15 | 0.140 |
Why?
|
| Monocytes | 1 | 2019 | 231 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 171 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2018 | 304 | 0.130 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 103 | 0.130 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2015 | 76 | 0.130 |
Why?
|
| Phlebography | 1 | 2017 | 67 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2020 | 2480 | 0.130 |
Why?
|
| Male | 16 | 2021 | 45870 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2020 | 644 | 0.120 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 72 | 0.120 |
Why?
|
| Disease Progression | 1 | 2020 | 1568 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1807 | 0.120 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 34 | 0.120 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2019 | 248 | 0.120 |
Why?
|
| Macrophages | 1 | 2019 | 626 | 0.120 |
Why?
|
| Heart Failure | 3 | 2016 | 1422 | 0.120 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 166 | 0.110 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 252 | 0.110 |
Why?
|
| Pericytes | 1 | 2013 | 14 | 0.100 |
Why?
|
| Adult | 8 | 2022 | 28718 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2016 | 314 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 257 | 0.100 |
Why?
|
| Calcium Carbonate | 1 | 2012 | 4 | 0.100 |
Why?
|
| Water Movements | 1 | 2012 | 8 | 0.100 |
Why?
|
| London | 1 | 2012 | 17 | 0.100 |
Why?
|
| Software | 1 | 2017 | 698 | 0.100 |
Why?
|
| Water Pollution | 1 | 2012 | 10 | 0.100 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2013 | 70 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2013 | 392 | 0.100 |
Why?
|
| Cell Communication | 1 | 2013 | 221 | 0.090 |
Why?
|
| Metals, Heavy | 1 | 2012 | 17 | 0.090 |
Why?
|
| RNA Interference | 1 | 2013 | 385 | 0.090 |
Why?
|
| Balloon Occlusion | 1 | 2012 | 33 | 0.090 |
Why?
|
| Tissue Scaffolds | 1 | 2013 | 129 | 0.090 |
Why?
|
| Endothelial Cells | 2 | 2013 | 482 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2781 | 0.090 |
Why?
|
| Water Supply | 1 | 2012 | 66 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 703 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 847 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2016 | 312 | 0.090 |
Why?
|
| Catheters | 2 | 2022 | 90 | 0.090 |
Why?
|
| Models, Chemical | 1 | 2012 | 187 | 0.090 |
Why?
|
| Swine | 2 | 2025 | 618 | 0.080 |
Why?
|
| Cell Movement | 1 | 2013 | 820 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2021 | 294 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 677 | 0.080 |
Why?
|
| In Vitro Techniques | 2 | 2022 | 1010 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2013 | 781 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2021 | 483 | 0.070 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 663 | 0.070 |
Why?
|
| Septal Occluder Device | 3 | 2013 | 56 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1534 | 0.070 |
Why?
|
| Nitrites | 1 | 2007 | 34 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2007 | 36 | 0.060 |
Why?
|
| Phenotype | 1 | 2013 | 2579 | 0.060 |
Why?
|
| Exercise Test | 1 | 2007 | 178 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 246 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2007 | 239 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 114 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2021 | 1546 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2007 | 727 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 910 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2025 | 41 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2004 | 52 | 0.060 |
Why?
|
| Fluoroscopy | 1 | 2025 | 138 | 0.050 |
Why?
|
| Critical Illness | 2 | 2021 | 346 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 501 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2004 | 169 | 0.050 |
Why?
|
| Animals | 4 | 2025 | 28945 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 3927 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2022 | 1034 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2004 | 233 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2004 | 263 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 395 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 3586 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 327 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2019 | 482 | 0.050 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2013 | 107 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 7232 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2021 | 32 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 136 | 0.040 |
Why?
|
| Prosthesis Design | 2 | 2013 | 310 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2022 | 156 | 0.040 |
Why?
|
| Mice | 2 | 2013 | 12562 | 0.040 |
Why?
|
| Peptides | 1 | 2004 | 672 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2022 | 196 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2022 | 254 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2022 | 10286 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 297 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 246 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 713 | 0.040 |
Why?
|
| Acoustics | 1 | 2019 | 51 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 413 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 157 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 424 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1268 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 2551 | 0.030 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 17 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 797 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1773 | 0.030 |
Why?
|
| Cannula | 1 | 2016 | 57 | 0.030 |
Why?
|
| Time Factors | 1 | 2025 | 5585 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 128 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 294 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 833 | 0.030 |
Why?
|
| Heart Atria | 1 | 2016 | 290 | 0.030 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2015 | 92 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 565 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 986 | 0.030 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 52 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1323 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2040 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 123 | 0.020 |
Why?
|
| United States | 2 | 2016 | 7767 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 935 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2883 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 707 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 2014 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 1503 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1981 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2004 | 10 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 2004 | 41 | 0.010 |
Why?
|
| Filgrastim | 1 | 2004 | 59 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 81 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2004 | 49 | 0.010 |
Why?
|
| Risk Factors | 2 | 2005 | 5960 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 163 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 324 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2943 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1666 | 0.010 |
Why?
|